Kaplan-Meier analysis of persistence and treatment switching data
| Total | Adalimumab | Golimumab | |
| N=183 | N=96 | N=87 | |
| Persistence data | |||
| Missing, n | 5 | 6 | |
| Events, n | 30 | 25 | |
| Censored, n | 61 | 56 | |
| Time from treatment initiation (months) | Patients remaining on treatment, (%) | ||
| 3 | 85.7 | 90.1 | |
| 6 | 76.9 | 80.2 | |
| 9 | 69.2 | 72.8 | |
| 12 | 67.0 | 69.1 | |
| Time (months) | |||
| 75% of patients remaining on treatment | 6.8 | 8.6 | |
| Switching data | |||
| Per cent of patients who stopped adalimumab or golimumab within 12 months, n (%) | 65 (35.5) | 34 (35.4) | 31 (35.6) |
| Per cent of patients who switched to another biologic within 12 months, n (%) | 37 (20.2) | 22 (12.0) | 15 (8.2) |
| Of those who switched, which biologic did they switch to? n (%) | |||
| N | 37 | 22 | 15 |
| Infliximab (Remicade) | 5 (13.5) | 2 (9.1) | 3 (20.0) |
| Infliximab biosimilar (Inflectra/Remsima) | 11 (29.7) | 6 (27.3) | 5 (33.3) |
| Vedolizumab (Entyvio) | 21 (56.8) | 14 (63.6) | 7 (46.7) |